Error loading player: No playable sources found

M104

Biological Reference Standards for Multivalent Vaccines: Qualification Strategies and Challenges from a National Control Lab Perspective

Date
April 27, 2020
This product is not available for individual purchase, but it is available as part of the following products:

Experience shows that the handling of compendial and especially non-compendial and in-house reference standards and materials are often a challenge for OMCLs (Official Medicines Control Labs). The qualification of biological reference materials by the manufacturer and the OMCL has a direct influence on the final results of analytical tests and is thus of extremely high importance. The replacement of the reference vaccine’ case study highlights the difficulties encountered by the manufacturers and National Control Labs dealing with biological materials and methods(e.g. :In vivo, ELISA), and how to overcome them.

Speaker

Speaker Image for Lorenzo Tesolin
Sciensano (Belgian Institute for Health

Related Products

Thumbnail for Bioassays for Cell and Gene Therapy
Bioassays for Cell and Gene Therapy
With increasing numbers of cell and gene therapy products in development and entering commercialization, more and more sponsors are facing a unique set of challenges of developing bioassays for cell and gene therapy products…
Thumbnail for Bioassays for New Therapies
Bioassays for New Therapies
The number and diversity of biotherapeutic modalities continues to increase. These represent complex modalities such as peptide and peptide conjugates, antisense oligonucleotides, DNA- and RNA-based therapies, drug conjugates, as well as viral vector-based therapeutics…
Thumbnail for Bioassays for Bispecifics – Double the Trouble or Double the Fun?
Bioassays for Bispecifics – Double the Trouble or Double the Fun?
The structures and functions of modern biotherapeutics are becoming increasingly complex…